Publications
2024
-
Mateo Sarmiento Bustamante, et al. "Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease." Haematologica. 2024 Jan 11 (online ahead of print). doi: 10.3324/haematol.2023.283603
-
Ayelet I Rubenstein, et al. "Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease." British Journal of Haematology. 2024 Jan 2 (online ahead of print). doi: 10.1111/bjh.19279
2023
-
Joshua D Brandstadter, et al. "A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease." European Journal of Immunology. 2023 Sep;53(9): e2250362. doi: 10.1002/eji.202250362
-
Stefano Rodolfi, et al. "Lymphadenopathy in the rheumatology practice: a pragmatic approach." Rheumatology (Oxford). 2023 Dec 18;kead644. doi: 10.1093/rheumatology/kead644
- Mateo Sarmiento Bustamante, Saishravan Shyamsundar, et al. "Ongoing symptoms following complete surgical excision in unicentric Castleman disease." American Journal of Hematology. 2023 Nov;98(11): E334-E337. doi: 10.1002/ajh.27065
- Ania Korsunska, et al. "A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases." Orphanet Journal of Rare Disease. 2023 Apr 11;18(1): 75. doi: 10.1186/s13023-023-02678-6
- Sheila K. Pierson, et al. "Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes." Blood Advances. 2023 Nov 14;7(21): 6652-6664. doi: 10.1182/bloodadvances.2023010745
- Natalie A. Mango, et al. "Siltuximab administration results in spurious IL-6 elevation in peripheral blood." American Journal of Hematology. 2023 Oct 23;99(1); E15-E18. doi: 10.1002/ajh.27132
- Pedro Horna, et al. "The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease." Haematologica. 2023 Jan 1;108(1): 207-218. doi: 10.3324/haematol.2021.280370
2022
- Christian Hoffmann, et al. "Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine." Vaccines (Basel). 2022 Oct 15;10(10):1725. doi: 10.3390/vaccines10101725
- David C. Fajgenbaum, et al. "The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry." British Journal of Haematology. 2022 Jul; 198(2): 307-316. doi: 10.1111/bjh.18214
- Joshua D Brandstadter and David C Fajgenbaum. "How we manage idiopathic multicentric Castleman disease."
Clinical Advances in Hematology Oncology. 2022 Sep;20(9): 564-571.
- Sheila K. Pierson, et al. "CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease." Nature Communications. 2022 Nov 24; 13(1):7236. doi. 10.1038/s41467-022-34873-7
- Anna Wing, et al. "Transcriptome and unique cytokine microenvironment of Castleman disease." Modern Pathology. 2022 Oct 22;35(4): 451-461. doi: 10.1038/s41379-021-00950-3
- Elizaveta Belyaeva, et al. "Bone Marrow Findings of Idiopathic Multicentric Castleman Disease: A Histopathologic Analysis and Systematic Literature Review." Hematological Oncology. 2022 Feb 1;40(2): 191-201. doi: 10.1002/hon.2969
- Alexis D. Phillips, et al. "Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO." Journal of Cellular & Molecular Medicine. 2022 Apr 30;26(11): 3174-3152. doi: 10.1111/jcmm.17251
- Mukherjee M, Martin R, et al. "Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy." Blood Adv. 2022 Jan 25;6(2): 359-367. doi: 10.1182/bloodadvances.2021004441
- Lu Zhang, et al. "A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD." Leukemia & Lymphoma. 2022 Jan 16;63(3): 618-626. doi: 10.1080/10428194.2021.1999437
2021
- Goodman AM, Jeong AR, et al. "Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease." European Journal of Hematology. 2021 Dec; 107(6): 642-649. doi: 10.1111/ejh.13702
- Nishimura Y, Fajgenbaum DC, et al. "Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease." Am J Hematol. 2021 Oct 1;96(10): 1241-1252. doi: 10.1002/ajh.26292
- Pierson SK, Shenoy S, et al. "Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease." Blood Adv. 2021 Sep 9;5(17): 3445-3456. doi: 10.1182/bloodadvances.2020004016.
- Lim JY, Duttke SH, et al. "DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells." J Exp Med. 2021 May 10;218(7): e20202733. doi: 10.1084/jem.20202733
- Koa B, Borja AJ, et al. "Emerging role of 18F-FDG PET/CT in Castleman disease: a review." Insights Imaging. 2021 Mar 11;12(1): 35. doi: 10.1186/s13244-021-00963-1
- Zhang MY, Jia MN, et al. "UCD with MCD-like inflammatory state: surgical excision is highly effective." Blood Adv. 2021 Jan 12;5(1): 122-128. doi: 10.1182/bloodadvances.2020003607
- Kawano M, Hara S, et al. "HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease." Rheumatology (Oxford). 2021 Jan 5;60(1): e3-e4. doi: 10.1093/rheumatology/keaa362
2020
- Abdallah H, Porterfield F, and Fajgenbaum DC. "Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man." BMJ Case Reports. 2020 Dec 13;13(12): e239825. doi: 10.1136/bcr-2020-239825
- Fajgenbaum DC, Wu D, et al. Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group. "Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease." Am J Hematol. 2020 Dec;95(12): 1553-1561. doi: 10.1002/ajh.25992.
- Fajgenbaum DC and Phillips AD. "Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia." Clin Chem. 2020 Nov 1;66(11): 1378-1379. doi: 10.1093/clinchem/hvaa156
- Fajgenbaum DC and Rader DJ. "Teaching Old Drugs New Tricks: Statins for COVID-19?" Cell Metab. 2020 Aug 4;32(2): 145-147. doi: 10.1016/j.cmet.2020.07.006.
- Fajgenbaum DC, Khor JS, et al. "Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review." Infect Dis Ther. 2020 Sep;9(3): 435-449. doi: 10.1007/s40121-020-00303-8
- Pai RL, Japp AS, et al. "Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease." JCI Insight. 2020 May 7;5(9): e135031. doi: 10.1172/jci.insight.135031
- Arenas DJ, Floess K, et al. "Increased mTOR activation in idiopathic multicentric Castleman disease." Blood. 2020 May 7;135(19): 1673-1684. doi: 10.1182/blood.2019002792
- Dispenzieri A and Fajgenbaum DC. "Overview of Castleman disease." Blood. 2020 Apr 16;135(16): 1353‐1364. doi: 10.1182/blood.2019000931
- Yoshimi A, Trippett TM, et al. "Genetic basis for iMCD-TAFRO." Oncogene. 2020 Feb 12;39(15): 3218‐3225. doi: 10.1038/s41388-020-1204-9
- Bernabei L, Waxman A, et al. "AA amyloidosis associated with Castleman disease: A case report and review of the literature." Medicine (Baltimore). 2020 Feb;99(6): e18978. doi: 10.1097/MD.0000000000018978
2019
- Suarez A, Reilly C, and Fajgenbaum DC. "Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era." Orphanet J Rare Dis. 2019 Jul 11;14(1): 173. doi: 10.1186/s13023-019-1145-y
- Fajgenbaum DC, Langan RA, et al. "Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease." J Clin Invest. 2019 Aug 13;129(10): 4451-4463. doi: 10.1172/JCI126091
- Nabel CS, Sameroff S. "Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease." PloS one. 2019 Jun 26;14(6): e0218660. doi: 10.1371/journal.pone.0218660
- Kobrin DM, Pinto AL, et al. "Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'." Acta Oncol. 2019;58(4): 515‐517. doi: 10.1080/0284186X.2019.1574980
- Zhang L, ZHao AL, et al. "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease." Blood. 2019 Apr 18;133(16): 1720-1728. doi: 10.1182/blood-2018-11-884577
- Zuccato M, Shilling D, and Fajgenbaum DC. "The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases." Emerg Top Life Sci. 2019 Mar 29;3(1): 97-105. doi: 10.1042/ETLS20180178
- Amélie L, Gnemmi V, et al. "Renal pathologic findings in TAFRO syndrome: Is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review." Front Immunol. 2019 Jun 28;10: 1489. doi: 10.3389/fimmu.2019.01489
- Morra DE, Pierson SK, et al. "Predictors of response to anti‐IL 6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data." British J Haematol. 2019 Jan;184(2): 232-241. doi: 10.1111/bjh.15588
2018
- Fajgenbaum DC. "Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease." Blood. 2018 Nov 29;132(22): 2323-2330. doi: 10.1182/blood-2018-05-848671
- Van Rhee F, Vorhees P, et al. "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease." Blood. 2018 Nov 15;132(20): 2115-2124. doi: 10.1182/blood-2018-07-862334
- Dong Y, Zhang L, et al. "Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease." Ann Hematol. 2018 Sep;97(9): 1641-1647. doi: 10.1007/s00277-018-3347-0
- Baker TS, Gambino K, et al. "A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease." Blood Adv. 2018 Nov 13;2(21): 2959-2963. doi: 10.1182/bloodadvances.2018023911
- Pierson SK, Stonestrom AJ, et al. "Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease." Am J Hematol. 2018 Jul;93(7): 902-912. doi: 10.1002/ajh.25123
- Lee J, Werth VP, et al. "Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference." Front Med (Lausanne). 2018 Nov 8;5: 306. doi: 10.3389/fmed.2018.00306
- Fajgenbaum DC, Shilling D. "Castleman Disease Pathogenesis." Hematol Oncol Clin North Am. 2018 Feb;32(1): 11-21. doi: 10.1016/j.hoc.2017.09.002
- Simon S, Fajgenbaum DC, et al. "Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology." Curr Res Transl Med. 2018 Sep;66(3): 83-86. doi: 10.1016/j.retram.2018.06.001
2017
- Louis C, Vijgen S, et al. "TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature." Front Med (Lausanne). 2017 Sep 22;4: 149. doi: 10.3389/fmed.2017.00149
- Srkalovic G, Marijanovic I, et al. "TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease." Bosn J Basic Med Sci. 2017 May 20;17(2): 81-84. doi: 10.17305/bjbms.2017.1930
- Yu L, Tu M, et al. "Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease." Blood. 2017 Mar 23;129(12): 1658-1668. doi: 10.1182/blood-2016-11-748855
- Fajgenbaum DC, Uldrick TS, et al."International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease." 2017 Mar 23;129(12): 1646-1657. doi: 10.1182/blood-2016-10-746933
- Behnia F, Elojeimy S, et al. "Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome." Ann Hematol. 2017 Mar;96(3): 497-500. doi: 10.1007/s00277-016-2875-8
2016
- Liu AY, Nabel CS, et al. "Idiopathic multicentric Castleman's disease: a systematic literature review." 2016 Apr;3(4): e163-75. doi: 10.1016/S2352-3026(16)00006-5
- Fajgenbaum DC, Ruth JR, et al. "The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research." 2016 Apr;3(4): e150-2. doi: 10.1016/S2352-3026(16)00007-7
- Iwaki N, Fajgenbaum DC, et al. "Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease." Am J Hematol. 2016 Feb;91(2): 220-6. doi: 10.1002/ajh.24242
- Fajgenbaum DC and Kurzrock R. "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease." Immunotherapy. 2016;8(1): 17-26. doi: 10.2217/imt.15.95
2015
- Newman SK, Jayanthan RK, et al. "Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research." Yale J Biol Med. 2015;88(4): 383‐388.
2014
- Fajgenbaum DC, van Rhee F, and Nabel CS. "HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy." Blood. 2014 May 8;123(19): 2924-33. doi: 10.1182/blood-2013-12-545087
- Fajgenbaum DC, Rosenbach M, et al. "Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue" [published correction appears in JAMA Dermatol. 2014 Apr;150(4): 460. Fajgenbaum David, [corrected to Fajgenbaum, David C]]. JAMA Dermatol. 2013;149(2):204‐208.